Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancers
H. Y. Khan, M. Nagasaka, Y. Li, A. Aboukameel, M. H. Uddin, R. Sexton, S. Bannoura, Y. Mzannar, M. N. Al-Hallak, S. Kim, R. Beydoun, Y. Landesman, H. Mamdani, D. Uprety, P. A. Philip, , A. S. Azmi
This paper shows that combining XPO1 inhibitor selinexor with KRAS G12C inhibitors enhances antitumor effects in preclinical models of KRAS G12C mutant cancers.
bioRxiv · Jan 26, 2022Cancer Biology